We are live on ! Find out more
HBIO icon

Harvard Bioscience

80 hedge funds and large institutions have $143M invested in Harvard Bioscience in 2018 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 27 increasing their positions, 25 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

278% more capital inflows, than outflows

Capital inflows: $24.2M | Capital outflows: $6.41M

113% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 8

13% more funds holding

Funds holding: 71 → 80 (+9)

8.91% more ownership

Funds ownership: 65.35% → 74.26% (+8.9%)

8% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 25

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
80
Holders Change
+9
Holders Change %
+12.68%
% of All Funds
1.82%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
17
Increased
27
Reduced
25
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

HBIO Hedge Fund Activity: Q2 2018 in Review

80 of the 4,386 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q2 2018, worth a combined $143M — up 23% from $116M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new HBIO positions and 8 closed out — a net gain of 9 holders — while 27 added to existing stakes and 25 trimmed.

The largest buyer was BlackRock, adding an estimated $7.71M. The largest seller was Foundry Partners, cutting an estimated $1.22M.

  • 80 institutional investors held Harvard Bioscience (HBIO) as of Q2 2018, up from 71 in Q1 2018.
  • Funds reported $143M of Harvard Bioscience stock for Q2 2018, up 23% quarter-over-quarter.
  • 17 funds opened new Harvard Bioscience positions in Q2 2018 and 8 closed out, a net change of +9 holders.
  • The largest Harvard Bioscience buyer in Q2 2018 was BlackRock, an estimated $7.71M added.
  • The largest Harvard Bioscience seller in Q2 2018 was Foundry Partners, an estimated $1.22M sold.

Based on aggregated 13F filings for Q2 2018.